Annual vaccination against influenza A and B viruses is recommended for everyone ≥6 months old without a contraindication.1 Available influenza vaccines for the 2021-2022 season are listed in Table 2.
Vaccination of all eligible persons can reduce the prevalence of influenza illness and symptoms that might be confused with those of COVID-19. Lower-than-usual rates of influenza illness have been observed this season in the Southern Hemisphere, probably because of masking, social distancing, school closures, and travel restrictions.2 According to the CDC, reduced immunity due to low influenza virus activity since March 2020 may...
- Azstarys (Serdexmethylphenidate/Dexmethylphenidate) for ADHD
- In Brief: Semglee - Insulin Glargine Interchangeable with Lantus
- In Brief: New Warnings for Janus Kinase Inhibitors
- Leuprolide Acetate (Fensolvi) for Central Precocious Puberty (online only)
- Belimumab (Benlysta) for Lupus Nephritis (online only)
- In Brief: Third Dose of mRNA-based COVID-19 Vaccines for Immunocompromised Persons
- Anifrolumab (Saphnelo) for Systemic Lupus Erythematosus
- Ozanimod (Zeposia) for Ulcerative Colitis
- In Brief: Higher-Dose Naloxone Nasal Spray (Kloxxado) for Opioid Overdose
RELEASE
The sodium-glucose cotransporter 2 (SGLT2) inhibitor empagliflozin (Jardiance – Boehringer Ingelheim) has been approved by the FDA for a third indication: to reduce the risk of hospitalization for heart failure (HF) and cardiovascular death in patients with heart failure with reduced ejection fraction (HFrEF), with or without type 2 diabetes. The SGLT2 inhibitor dapagliflozin ...
